| Value | ₹1,104 Cr |
|---|
NSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,777.70
- Market cap
- ₹4,26,530 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.3×Sector 45.9×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Other price movement clarification announcements
All →Olatech Solutions Price Movement Clarification
Olatech Solutions said its share price movement was purely market driven, responding to a BSE query. It stated it remains compliant with Regulation 30 disclosures.
Black Opal Consultants Price Movement Clarification
Black Opal Consultants clarified to BSE on recent share price movement. It says no pending price-sensitive information exists and the move appears market-driven.
SJP Ultrasonics Price Movement Clarification
SJP Ultrasonics clarified to BSE that it is unaware of any undisclosed price-sensitive information behind a recent significant share price movement. It cannot comment on the causes, which it attributes to market factors.
Filtron Engineers Price Movement Clarification
Filtron Engineers says its recent share price movement is market-driven and no price-sensitive information is pending. It replies to a BSE query dated 29 October 2026.
Century Business Media Price Movement Clarification
Century Business Media is unaware of any reason for its recent share price movement. It attributes the move to market conditions.
Suzlon Energy Price Movement Clarification
Suzlon Energy reported a material price movement on 30 Oct 2026. The company stated no identifiable event or media report triggered the move.